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POEMSsyndromeisarareparaneoplasticdisorderassociatedwithanunderlyingplasmacelldyscrasiapresentingpolyneuropathy,
organomegaly, endocrinopathy, monoclonal protein, and skin changes. This study reviewed the clinical characteristics of 14
POEMS patients in Zhongshan hospital. The ratio of male to female was 9:5, and the average age was 47.1 years. The
clinicalmanifestationswerevarious,includingmotorialsymptoms(weakness),sensorysymptoms(numbness),lymphadenopathy,
edema, abdominal distention, and skin hyperpigmentation. Imaging studies and laboratory tests also exhibited hepatomegaly,
splenomegaly, thrombocytosis, endocrinopathy, and positive serum immunoﬁxation in most patients. In addition, increased
plasma cells in bone marrow and Castleman Disease were found in bone marrow and lymph nodes biopsies. All the eight follow-
up patients were treated with alkylator-based combination chemotherapy or corticosteroids and thalidomide, with or without
autologous stem cell transplantation. Unfortunately, two patients died three or four years after diagnosis of POEMS syndrome.
The others showed response to therapy to some extent, but not completely remission. Currently, treatments for POEMS include
radiation to the plasmacytoma, and systemic therapy is indicated. Low-dose alkylators with or without corticosteroids are eﬀective
in some patients. However, high-dose chemotherapy with auto-SCT dramatically improved symptoms and outcomes for POEMS
patients.
1.Introduction
POEMS syndrome is a rare paraneoplastic disorder asso-
ciated with an underlying plasma cell dyscrasia [1]. The
acronym POEMS refers to frequently occurring features
of the syndrome, including polyneuropathy, organomegaly,
endocrinopathy, monoclonal protein (M-protein), and skin
changes [1–5]. It was also called osteosclerotic myeloma,
Crow-Fukase syndrome, and Takatsuki syndrome [3, 6]a n d
was ﬁrst reported by Scheinker in 1938 [3, 7]. In 1986, the
ﬁrst Chinese case of POEMS syndrome had been described
[8]. Here, we report 14 clinical cases of POEMS syndrome
in Zhongshan Hospital, Fudan University, and review of the
literature.
2. Patientsand Methods
From2005to2010,14POEMSpatientswereadmittedtoour
hospital. All 14 patients met the diagnosis criteria proposed
by Nakanishi et al. in 1984 [3] or Dispenzieri et al. in 2003
[9]. Nankanish et al. in 1984 ﬁrst proposed the criteria
of POEMS syndrome containing polyneuropathy, organo-
megaly(hepatomegaly,splenomegaly,orlymphadenopathy),
endocrinopathy (hypothyroidism, diabetes mellitus, hy-
poadrenocorticism, or hypogonadism), M-protein, skin
changes (hyperpigmentation, hypertrichosis, or thickening),
and eﬀusion or peripheral edema. At least three of these
six criteria are required for diagnosis. Dispenzieri et al. [9]
in 2003 suggested the criteria for the diagnosis of POEMS
syndrome. The major criteria included polyneuropathy and
monoclonal plasmaproliferative disorder. The minor criteria
included sclerotic bone lesions, Castleman disease, organo-
megaly, edema, endocrinopathy, skin changes, and papille-
dema. Two major criteria and at least 1 minor criterion are
required to diagnose POEMS syndrome.
We analyzed their general information, symptoms and
signs, laboratory tests, therapy, and survival. Eight of the 14
patients got followed up in the clinic or by telephone for
survival. The last follow-up day was August 4, 2011.2 ISRN Gastroenterology
Table 1: Clinical features of 14 patients.
Polyneuropathy
Peripheral neuropathy 14/14
Papilledema 5/10
Organomegaly
Hepatomegaly 8/14
Splenomegaly 11/14
Lymphadenopathy 7/14
Endocrinopathy
Hypothyroidism 10/14
Amenorrhea 1/14
Impotence 2/14
Hypoadrenocorticism 1/14
Hypoparathyroidism 1/14
M-protein
IgA λ 6/13
IgA κ 1/13
IgM λ 1/13
IgG λ 2/13
Skin change
Hyperpigmentation 11/14
Pruritus 2/14
Edema
Peripheral edema 7/14
Eﬀusions 10/14
Ascites
Pleural eﬀusion 8/14
Hydropericardium 8/14
3. Result
3.1. General Conditions and Clinical Manifestations. From
2005 to 2010, 14 patients were diagnosed of POEMS syn-
drome in our hospital. The ratio of male to female was 9:5,
and the average age was 47.1 years (range: 39–68 years). The
initial clinical manifestation in this study was multifarious,
including motorial symptoms (weakness) (57.1%), sensory
symptoms (numbness) (35.7%), skin hyperpigmentation
(78.6%), edema (50%), and abdominal distention (37.3%).
The typical clinical features of these patients were listed in
Table 1.
3.1.1. Polyneuropathy. All the patients had peripheral neu-
ropathy conﬁrmed by nerve conduction/EMG studies.
Among these patients, eight had motorial deﬁcit (57.1%),
while ﬁve had sensory deﬁcit (35.7%). Meanwhile, ﬁve pa-
tients (35.7%) presented sensorimotor deﬁcit.
3.1.2. Organomegaly. Organomegaly was the universal signs
of all the patients (92.9%), in which splenomegaly (84.6%)
was more common than hepatomegaly (61.5%) and lym-
phadenopathy (50.0%). Multiorganomegaly could be seen in
76.9% of them.
3.1.3. Endocrinopathy. Among the 14 patients of POEMS
syndrome, 10 patients suﬀering from endocrinopathy all
presented as hypothyroidism. In these patients, one had
amenorrhea, two had impotence, one had hypoadrenocor-
ticism, and one had hypoparathyroidism.
3.1.4. Monoclonal Plasmaproliferative Disorder. Of the 13
patients who had serum immunoﬁxation detection, ten
(76.9%) showed positive results of monoclonal plasma pro-
liferative disorder. Six patients had abnormal immunoglob-
ulin A (IgA) λ,t w oh a dI g Gλ,o n eh a dI g Aκ, and the rest
had IgM λ. Another patient had both serum IgG and IgA
elevation, while serum immunoﬁxation remained negative.
3.1.5.SkinChanges. Ofallthe14patients,themostcommon
abnormality was hyperpigmentation (11 patients, 78.6%),
followed by pruritus (two patients, 14.2%).
3.1.6.EdemaandEﬀusions. Inourstudy,mostofthepatients
had edema and eﬀusions of varying degrees. Seven had
peripheral edema (50%), and 11 had serouscavity eﬀusions
(78.6%) including ascites (71.4%), pleural eﬀusion (57.1%),
hydropericardium (57.1%). Multiple serous cavity eﬀusions
were present in nine patients (64.3%).
3.1.7.Papilledema. Tenpatientsunderwentfundusexamina-
tion, and ﬁve were diagnosed with papilledema.
3.2. Accessory Examination. Blood routine and urinalysis of
the 14 patients revealed that ﬁve of them had thrombocytosis
(35.7%), two had microscopic haematuria (14.3%), and four
had proteinuria (28.6%). Renal insuﬃciency occurred in ﬁve
patients (35.7%). One of them experienced renal biopsy and
was diagnosed with IgA nephropathy.
Laboratory tests exhibited that 10 patients had thy-
roid hypofunction. Hypoadrenocorticism and hypoparathy-
roidism were seen in individual patient. The concentration
of gonadal hormone lowered signiﬁcantly in two patients (1
male and 1 female).
Three of the seven patients who had lymphadenopathy
underwent lymph node biopsy. All were diagnosed with
Castleman disease histopathologically. One sample showed
λ-light chain (+) after immunohistochemical staining indi-
cating monoclonal plasmaproliferative disorder.
Nerve conduction/EMG studies of all patients showed
prolongeddistalmotoriallatencyandslowedvelocityofboth
motorial and sensory nerve conduction. One patient had
sural nerve biopsy and showed inﬁltration of lymphocytes
around vessels in epineurium and partial demyelination
while neuraxon intact.
Among the 14 patients, 11 had bone marrow aspiration.
Two patients (18.2%) had a slight increase in plasma cells
(more than 2%). Two (18.2%) had more than 5% plasma
cells, but no deﬁnite signs of multiple myeloma. The rest had
normal plasma cells. In patients who had radiographic bone
survey and isotope bone scan, no sclerotic or lytic lesions
were found.ISRN Gastroenterology 3
Three of the eight follow-up patients were treated with
alkylator-based combination chemotherapy. Five patients
were treated with corticosteroids and thalidomide, and one
also had autologous stem cell transplantation (auto-SCT).
Two patients treated by alkylator-based combination chem-
otherapy died three or four years after the diagnosis of
POEMS syndrome. All the others were responsive to therapy
to some extent but not completely relieved.
4. Discussion
POEMS syndrome was ﬁrst reported by Scheinker in 1938
[3, 7]. It is a multisystem disorder associated with polyneu-
ropathy, organomegaly, endocrinopathy, M-protein, and
skin changes [10, 11]. Elevation of proangiogenic and pro-
inﬂammatory cytokines are the hallmark in the pathogenesis
of this disorder [12–15]. High levels of interlcukin-1β (IL-
1β), interlcukin-6 (IL-6), tumor necrosis factor-α (TNF-
α), and vascular endothelial growth factor (VEGF) were
detected in the serum of POEMS patients [12–15]. Among
thesecytokines,VEGF,probablyoversecretedbyplasmacells,
appears to be the dominant driving cytokine and may be
causative for eﬀusions, pulmonary hypertension, and DIC in
POEMS syndrome [16, 17].
Dispenzieri et al. investigated 99 patients in 2003. The
median age and the ratio of men to female were similar to
that of our study. The major clinical feature of this syndrome
is a chronic progressive polyneuropathy with a predominant
motorial disability [1]. In our study, the initial symptoms
of most patients were sensory and also motorial symptoms
(Table 1). However, all of the 14 patients were diagnosed
withpolyneuropathybynerveconduction/EMGstudieseven
including those who did not complain about numbness or
dysesthesias. The neuropathy is usually symmetrical and
ascending, with either insidious or rapidly progressing onset
[9], and ﬁnally POEMS patients may be conﬁned to a wheel-
chair.
Organomegaly usually aﬀects the liver, the spleen, and
the lymph nodes. Among our patients, the splenomegaly was
the most common symptom (84.6%), which mirrors to the
report of Cui et al. [10]. Nevertheless, Li et al. [18]r e v i e w e d
the clinical characteristics of 99 Chinese POEMS patients
and found 74 patients with lymphadenopathy, 70 with sple-
nomegaly, and 47 with hepatomegaly. Dispenzieri et al. de-
scribed that the liver was palpable in almost one-half of
patients, but splenomegaly and lymphadenopathy were
found in fewer patients [1].
The M-protein is typically small (median 1.1g/dL, rarely
more than 3.0g/dL) and remains undetected on serum-
protein electrophoresis without immunoﬁxation. The M-
protein is usually IgG or IgA and almost of the lambda type
[1, 10]. According to Dispenzieri et al. [9], all patients had
evidence of a monoclonal plasmaproliferative disorder, and
87% had a detectable M-protein in their serum or urine
by immunoﬁxation. For the 12 patients whose serum or
urine M-protein remained undetected, the expression of M-
proteinwasdemonstratedbyimmunohistochemicalstaining
of biopsy specimens from sclerotic bone lesions or bone
marrow. In our study, 10 out of 13 patients (76.9%) had a
visibleM-proteinbyimmunoﬁxation.Theincidenceofthose
wassigniﬁcantlylowerthanreportedbyDispenzierietal.[9].
Among these 10 patients, one patient was further veriﬁed
λ (+) by immunohistochemical stain of his lymphonode
biopsy specimen. We should ﬁnd more positive M-protein
in other patients if we could check the serum or urine
immunoﬁxation repeatedly or proceed with immunohisto-
chemical stain on biopsy samples of lympho node, sclerotic
bone lesions, or bone marrow.
Our research exhibited that 14.3% and 28.6% of the
patients had hematuria and proteinuria. Elevated Cr level in
serum was detected in 35.7% of our patients, indicating that
POEMS may lead to renal impairment or even renal failure.
The result was similar to the report of Li et al. [18]. The
histopathologic alteration of glomerulus usually present as
membranoproliferative glomerulonephritis (MPGN) [19].
Based on the impacts of IL1-β and IL-6 as the mediators of
endothelial cell activation, especially VEGF as an endothelial
cell mitogen and an inducer of microvascular permeability,
an endothelial cell-mediated injury is more likely to be im-
plicated in the pathogenesis of this syndrome [14, 18, 20].
In our study, majority of our patients did not have
radiographic bone survey owing to our tight turnover rate.
According to Dispenzieri et al. [9], 97% of their patients
had at least one abnormality detected on bone radiography.
About half of patients had mixed sclerotic and lytic lesions.
Apart from the above, the important traits of POEMS
syndrome include elevated levels of VEGF, sclerotic bone
lesions, Castleman disease, papilledema, peripheral edema,
ascites, eﬀusions, thrombocytosis, and polycythemia [1]. In
addition, we found that Castleman disease, papilledema, pe-
ripheral edema, ascites, eﬀusions, and thrombocytosis were
also common manifestations.
Based on the earlier criteria in 2003 [9], Dispenzieri
[1] revised the diagnostic criteria of POEMS syndrome in
2007. He proposed that sclerotic bone lesions, Castleman
disease, and elevated levels of VEGF as major diagnostic
criteria. Apart from polyneuropathy and monoclonal plasma
cell disorder, in order to make diagnosis at least one other
major criterion and 1 minor criterion are required.
Currently, the treatments for POEMS syndrome include
radiation, alkylators, corticosteroids, auto-SCT, bevacizum-
ab, rituximab, bortezomib, and thalidomide [2, 21–30]. In
patients with a dominant sclerotic plasmacytoma, ﬁrst-line
therapy should contain radiation therapy to the lesion. For
those patients with systemic manifestation, systemic therapy
is indicated. Low dose alkylators with or without corticos-
teroids are eﬀective in some patients. Furthermore, high-
dose chemotherapy with auto-SCT dramatically improved
manifestations and outcomes for POEMS patients [2, 21, 24,
31].
In 2009, Ohwada et al. [29] reported the ﬁrst case of
successful combination induction therapy of bevacizumab
(anti-VEGF MoAb) and thalidomide, followed by Auto-SCT.
Bevacizumab could induce a dramatic decrease in the serum
VEGF level, and thereby reduce pleural eﬀusion and ascites
with thalidomide to maintain low VEGF level. In summary,
bevacizumab is eﬃcacious for POEMS syndrome, when it4 ISRN Gastroenterology
is used in combination with other chemotherapeutics at the
earlier stage.
Another successful case of POEMS syndrome associated
with Waldenstrom macroglobulinemia (WM) was treated by
rituximab with thalidomide [26], which eﬀectively decreased
CD20-positive lymphoplasmacytic cells and improved pa-
tient’s neurological symptoms.
TheclinicalcourseofPOEMSsyndromeischronic.A93-
patient follow-up data revealed that the median survival of
patients with POEMS syndrome is 165 months [9]. Another
research in China showed 80% patients were alive after
follow-up time of 25 months, and 10% patients had survived
more than 60 months [18]. The neuropathy, along with
stroke and myocardial infarction, is the cause of death at last
[1, 9].
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